Emanera (esomeprazole) enteric capsules 40 mg. №28

$75.00

Manufacturer: Spain

adults Gastroesophageal reflux disease (GERD): treatment of erosive reflux-esophagitis; long-term treatment of patients with cured esophagitis to prevent relapse; symptomatic treatment of gastroesophageal reflux disease (GERD). In combination with appropriate antibacterial drugs for the eradication of Helicobacter pylori: treatment of duodenal ulcer caused by Helicobacter pylori; preventing the recurrence of peptic ulcers in patients with ulcers caused by Helicobacter pylori . Patients requiring long-term use of non-steroidal anti-inflammatory drugs (NSAIDs): healing of stomach ulcers caused by NSAIDs; prevention of gastric and duodenal ulcers caused by NSAIDs in patients at risk.

Category:

Description

Emanera Composition
active substance: esomeprazole;

1 capsule enteric 40 mg esomeprazole (as esomeprazole magnesium dihydrate);

Emanera excipients: spherical sugar (contains sucrose), povidone, sodium lauryl sulfate, opadray II white 85F28751, magnesium carbonate, methacrylate copolymer dispersion, talc, macrogol 6000, titanium dioxide (E 171), polysorbate 80, iron oxide red (E172), gelatin …

Emanera Dosage form
Enteric capsules.

Basic physical and chemical properties: the base and the cap of the capsule are pink; the contents of the capsule are white or almost white granules.

Pharmacotherapeutic group
Means for the treatment of peptic ulcer and gastroesophageal reflux disease. Proton pump inhibitors. ATX code А02В С05.

Pharmacodynamics
Esomeprazole is the S-isomer of omeprazole, which reduces the secretion of hydrochloric acid in the stomach due to a specific, targeted mechanism of action. It is a specific inhibitor of the proton pump of parietal cells. Both the R- and S-isomers of omeprazole exhibit similar pharmacodynamic activity.

Mechanism of action

Esomeprazole is a weak base, concentrated and converted into an active form in the highly acidic environment of the secretory tubules of parietal cells, where it inhibits the enzyme H + K + ATP-ase – the proton pump – and suppresses both basal and stimulated acid secretion.

After oral administration of 20 and 40 mg of esomeprazole, the onset of action of the drug is observed within one hour.

After repeated use of 20 mg of esomeprazole once a day for five days, on the fifth day, the average maximum acid secretion after stimulation with pentagastrin decreases by 90% when measured 6-7 hours after taking the drug.

After five days of oral esomeprazole 20 mg and 40 mg orally in patients with symptomatic GERD over a 24-hour period, intragastric pH levels above 4 were maintained for an average of 13 and 17 hours, respectively. The proportion of patients in whom, after taking esomeprazole at a dose of 20 mg, the gastric pH was maintained at a level of more than 4 for 8, 12 and 16 hours was 76%, 54% and 24%, respectively. The corresponding proportions of patients with esomeprazole 40 mg were 97%, 92% and 56%.

Indications
Adults

Gastroesophageal reflux disease (GERD):

treatment of erosive reflux esophagitis;
long-term treatment of patients with healed esophagitis to prevent recurrence;
symptomatic treatment of gastroesophageal reflux disease (GERD).
In combination with appropriate antibacterial drugs for the eradication of Helicobacter pylori:

treatment of duodenal ulcer due to Helicobacter pylori;
prevention of recurrence of peptic ulcers in patients with ulcers caused by Helicobacter pylori.
Patients requiring long-term use of non-steroidal anti-inflammatory drugs (NSAIDs):

healing of stomach ulcers caused by the use of NSAIDs;
prevention of stomach and duodenal ulcers caused by the use of NSAIDs in patients at risk.
Long-term treatment after intravenous administration of the drug to prevent recurrence of bleeding from peptic ulcers.

Treatment of Zollinger-Ellison syndrome.

Children over 12 years old

Gastroesophageal reflux disease (GERD):

treatment of erosive reflux esophagitis;
long-term treatment of patients with healed esophagitis to prevent recurrence;
symptomatic treatment of gastroesophageal reflux disease (GERD).
In combination with antibiotics in the treatment of duodenal ulcer due to Helicobacter pylori

Contraindications
Hypersensitivity to the active ingredient, substituted benzimidazoles or to any of the excipients.

Esomeprazole should not be used concomitantly with nelfinavir (see Section “Interaction with other medicinal products and other forms of interaction”).